Avastin Misses Key Data Point in Brain Cancer Study - Drugs.com ...

From Balochistan Times (Pakistan) (January 15, 2013)

Swiss drugmaker Roche's cancer drug Avastin failed to make a statistically significant difference to survival rates of patients with a common form of brain cancer in a late-stage study, the company said on Saturday.

The Phase III AVAglio study presented at the Society for Neuro-Oncology congress in Washington on Saturday showed Avastin, combined with radiation and chemotherapy, reduced the risk of cancer worsening or death, the Basel-based drugmaker said in a news release.

But the drug did not reach statistical significance in overall survival, a key data point. Further data are expected next year, Roche said.

"The interim results for overall survival (OS), the other co-primary endpoint, did not reach statistical significance," the company said in the statement.

Earlier data from the study published in August showed Avastin significantly extended progression-free survival of people with an aggressive form of brain cancer.

Avastin is Roche's third-biggest seller and is approved to treat several types of cancer, including breast, kidney, colorectal and ovarian cancers.

?

Posted: January 2013

View comments

Source: http://www.drugs.com/news/avastin-misses-key-data-point-brain-cancer-study-42546.html

apple dividend snow white and the huntsman snow white and the huntsman rupaul drag race walking dead comic kratom broncos